| Name | Tisolagiline |
| Description | Tisolagiline (KDS2010) is a potent, highly selective and reversible MAO-B inhibitor with IC50=8 nM and oral activity for the treatment of Alzheimer's disease and obesity. |
| In vitro | Tisolagiline demonstrated high potency in inhibiting MAO-B in human cell assays, with an IC₅₀ of 8.0 nM, showing over 1,250-fold selectivity for MAO-B over MAO-A[1]. |
| In vivo | In a MPTP-induced Parkinson’s disease mouse model, oral administration of Tisolagiline (10 mg/kg/day for 5 days) significantly protected dopaminergic neurons in the substantia nigra and improved motor function. Furthermore, chronic administration in non-human primates (cynomolgus monkeys) showed favorable pharmacokinetics and safety at doses up to 100 mg/kg/day for 4 weeks, with reversible MAO-B inhibition and no significant adverse effects observed[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 3.3 mg/mL (10.24 mM), Sonication is recommended.
DMSO : 80 mg/mL (248.19 mM), Sonication is recommended.
|
| Keywords | Tisolagiline | MonoamineOxidase | Monoamine Oxidase | KDS-2010 |
| Inhibitors Related | Safinamide | 1,4-Naphthoquinone | 4-Chlorochalcone | Paeonol | Hydroxylamine hydrochloride | Isatin | Methylene Blue trihydrate | β-Aminopropionitrile | Aminoacetone hydrochloride | Allylthiourea | D-(-)-Quinic acid | Amitraz |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
